This page shows the latest COVID-19 testing news and features for those working in and with pharma, biotech and healthcare.
J&J advanced its COVID-19 vaccine candidate into phase 3 testing in September following positive interim results from a phase 1/2a clinical study of the shot. ... The pivotal late-stage study is investigating the safety and efficacy of a single vaccine
Johnson &Johnson (J&J) announced on Wednesday that it will decrease the size of its US-based phase 3 trial currently testing its COVID-19 vaccine as cases surge across the ... J&J advanced its COVID-19 vaccine candidate into phase 3 testing in September
The company is expecting interim data from this trial as early as the first quarter of 2021, but this depends on the overall COVID-19 infection rate in the region. ... As Novavax seeks to move NVX-CoV2373 through late-stage testing, a number of COVID-19
Trial will test therapeutic candidates in hospitalised COVID-19 patients. The COVID-19 R&D Alliance has enrolled the first patient in a trial testing therapeutic candidates from Amgen, UCB and ... Takeda. The COMMUNITY trial is testing a number of drugs
ENSEMBLE study will enrol 60, 000 people worldwide. Johnson &Johnson (J&J) has launched a second phase 3 trial of a single-dose regimen of its COVID-19 vaccine candidate, ... AstraZeneca, which is developing its COVID-19 vaccine in conjunction with
This hyper inflammation can seriously harm patients with COVID-19 and can result in the death of patients. ... Aside from Calquence, AZ is also testing a late-stage COVID-19 vaccine candidate, originally developed by Oxford University researchers, which
More from news
Approximately 1 fully matching, plus 25 partially matching documents found.
when/the extent to which countries were most significantly impacted by COVID-19. ... Although some level of face-to-face interaction is returning, this interaction:. is likely to come with additional requirements for company representatives for COVID-19
Encouraged by this initial data, Sanofi and Rengeneron decided to take their own IL-6 inhibitor, Kevzara (sarilumab), into clinical testing for COVID-19. ... patients with COVID-19, as appropriate, when a clinical trial is not available or feasible”.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Outside of COVID-19 research, clinical trials are being impacted regardless of indication. ... COVID-19 testing is not part of trial protocols and patients may need to be removed from study populations for safety reasons.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...